Cassava Sciences Inc (NASDAQ:SAVA) — Market Cap & Net Worth
Market Cap & Net Worth: Cassava Sciences Inc (SAVA)
Cassava Sciences Inc (NASDAQ:SAVA) has a market capitalization of $58.21 Million ($58.21 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21427 globally and #4819 in its home market, demonstrating a -20.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cassava Sciences Inc's stock price $1.21 by its total outstanding shares 48307896 (48.31 Million). Also see SAVA total assets for a full breakdown of the balance sheet.
Cassava Sciences Inc Market Cap History: 2015 to 2026
Cassava Sciences Inc's market capitalization history from 2015 to 2026. Data shows change from $591.77 Million to $58.21 Million (-20.20% CAGR). Also see SAVA cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Cassava Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #622 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2055 of 3165 |
Weight: Cassava Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cassava Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cassava Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SAVA stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
-792786.25x
Cassava Sciences Inc's market cap is -792786.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.43 Billion | $-1.80K | -$72.47 Million | -792786.25x | N/A |
Competitor Companies of SAVA by Market Capitalization
Companies near Cassava Sciences Inc in the global market cap rankings as of September 18, 2026. Review SAVA goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Cassava Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Cassava Sciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cassava Sciences Inc's market cap moved from $591.77 Million to $ 58.21 Million, with a yearly change of -20.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $58.21 Million | -39.14% |
| 2025 | $95.65 Million | -16.10% |
| 2024 | $114.01 Million | -89.52% |
| 2023 | $1.09 Billion | -23.80% |
| 2022 | $1.43 Billion | -32.40% |
| 2021 | $2.11 Billion | +540.76% |
| 2020 | $329.46 Million | +31.15% |
| 2019 | $251.20 Million | +511.76% |
| 2018 | $41.06 Million | -78.75% |
| 2017 | $193.23 Million | +0.25% |
| 2016 | $192.75 Million | -67.43% |
| 2015 | $591.77 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Cassava Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.21 Million USD |
| MoneyControl | $58.21 Million USD |
| MarketWatch | $58.21 Million USD |
| marketcap.company | $58.21 Million USD |
| Reuters | $58.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more